Post Operative Nausea And Vomiting – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Post Operative Nausea And Vomiting – Pipeline Review, H2 2016’, provides an overview of the Post Operative Nausea And Vomiting pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post Operative Nausea And Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post Operative Nausea And Vomiting and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Post Operative Nausea And Vomiting

The report reviews pipeline therapeutics for Post Operative Nausea And Vomiting by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Post Operative Nausea And Vomiting therapeutics and enlists all their major and minor projects

The report assesses Post Operative Nausea And Vomiting therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Post Operative Nausea And Vomiting

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Post Operative Nausea And Vomiting

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Post Operative Nausea And Vomiting pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acacia Pharma Ltd

Camurus AB

GW Pharmaceuticals Plc

INSYS Therapeutics Inc

Suda Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Post Operative Nausea And Vomiting Overview 6

Therapeutics Development 7

Pipeline Products for Post Operative Nausea And Vomiting - Overview 7

Post Operative Nausea And Vomiting - Therapeutics under Development by Companies 8

Post Operative Nausea And Vomiting - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Unknown Stage Products 11

Post Operative Nausea And Vomiting - Products under Development by Companies 12

Post Operative Nausea And Vomiting - Companies Involved in Therapeutics Development 13

Acacia Pharma Ltd 13

Camurus AB 14

GW Pharmaceuticals Plc 15

INSYS Therapeutics Inc 16

Suda Ltd 17

Post Operative Nausea And Vomiting - Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Combination Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 27

(buprenorphine hydrochloride + granisetron hydrochloride) - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

amisulpride - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

nabiximols - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

ondansetron hydrochloride - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

ondansetron hydrochloride - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Post Operative Nausea And Vomiting - Dormant Projects 41

Post Operative Nausea And Vomiting - Discontinued Products 42

Post Operative Nausea And Vomiting - Product Development Milestones 43

Featured News & Press Releases 43

Aug 12, 2016: Positive Results From Pivotal Phase 3 Trial of BAREMSIS For The Treatment of PONV 43

Mar 21, 2016: Initiation of Second Pivotal Phase 3 Treatment Trial with BAREMSIS (APD421) in PONV 43

Jan 05, 2016: Positive Results From Second Pivotal Phase 3 Study Of BAREMSIS (APD421) In PONV 44

Apr 21, 2015: Phase 3 Combination Prophylaxis Study Initiated With APD421 In PONV 45

Oct 07, 2014: Acacia Pharma Announces Positive Phase 3 Results For APD421 in Post-Operative Nausea & Vomiting 46

Sep 17, 2013: Acacia Pharma Initiates Pivotal Phase 3 Studies with APD421 in Post-Operative Nausea & Vomiting 46

May 28, 2012: Acacia Pharma Announces Positive Results For APD421 In Post-Operative Nausea & Vomiting 47

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

List of Tables

Number of Products under Development for Post Operative Nausea And Vomiting, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Unknown Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Post Operative Nausea And Vomiting – Pipeline by Acacia Pharma Ltd, H2 2016 13

Post Operative Nausea And Vomiting – Pipeline by Camurus AB, H2 2016 14

Post Operative Nausea And Vomiting – Pipeline by GW Pharmaceuticals Plc, H2 2016 15

Post Operative Nausea And Vomiting – Pipeline by INSYS Therapeutics Inc, H2 2016 16

Post Operative Nausea And Vomiting – Pipeline by Suda Ltd, H2 2016 17

Assessment by Monotherapy Products, H2 2016 18

Assessment by Combination Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 26

Post Operative Nausea And Vomiting – Dormant Projects, H2 2016 41

Post Operative Nausea And Vomiting – Discontinued Products, H2 2016 42

List of Figures

List of Figures

Number of Products under Development for Post Operative Nausea And Vomiting, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 10

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Stage and Molecule Types, H2 2016 26

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports